 |
 |
|||||||||||||||||||
 |
||||||||||||||||||||
 |
 |
|
||||||||||||||||||
|
|
|||||||||||||||||||
|
||||||||||||||||||||
|
|
|||||||||||||||||||
|
|
|
|
|
|
|||||||||||||||
Wen-Jen Hwu, MD, PhD, is Associate Attending Physician at Memorial Sloan-Kettering Cancer Center, New York, New York.
Lynne A. Lamb, RN, MSN, is Clinical Research Nurse at Memorial Sloan-Kettering Cancer Center, New York, New York.
Order the free CD-ROM activity Innovations in Oncology: Immunomodulatory Therapy for Malignant Melanoma.
Minimum system requirements: a PC with a 300-MHz Pentium II or equivalent processor, 64 MB of RAM, a 56-kbps modem, a CD-ROM drive, a sound card, and the following software (or later versions) installed: Microsoft Windows 98, Internet Explorer 5 or Netscape Navigator 6, and Macromedia Flash Player 5. Additionally, Adobe Acrobat Reader 5 or later is required if you wish to view or print the included PDF files. Use of this CD-ROM on a Macintosh computer is not supported.
Provided by Meniscus
Educational Institute, a division of Meniscus Limited.
Supported by an educational grant from Celgene Corporation.
Release date: January 31, 2004
CE available until: July 31, 2005
This educational activity is designed for oncologists and oncology nurses who care for patients with malignant melanoma.
Activity Rationale and Purpose
Malignant melanoma represents 2% of all cancers in the United States, and its incidence is increasing. Metastatic melanoma is incurable, and patient survival is often brief. Standard chemotherapy currently consists of dacarbazine, with a response rate of approximately 15%. Combination chemotherapy with dacarbazine has not yielded improved response or survival benefits. The need for improved treatment options has led to consideration of the role of immunomodulatory agents in the treatment of metastatic malignant melanoma. Oncology health care professionals need to be aware of the latest therapeutic options and clinical outcomes. The overall purpose of this educational activity is to provide the latest clinical information on the role of immunomodulatory agents in the treatment of metastatic melanoma.
After participating in this activity, health care professionals should be able to
- Explain currently accepted management strategies for patients with metastatic malignant melanoma and relate how immunomodulatory agents fit into these strategies
- Summarize new agents and combination therapies for patients with malignant melanoma
- Identify characteristics that might make patients appropriate candidates for novel therapies
- Define how treatment options impact key quality of life issues for patients with malignant melanoma
- Describe patient management and education strategies for patients being treated for malignant melanoma
When choosing among continuing education activities, clinicians should select those that are appropriate for their educational needs. Participants in educational activities have the implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional effectiveness. Clinicians should reflect on this activity and its applicability to their own patient population, and then identify and implement appropriate practice changes.
Statements of
Credit.—Participants who successfully complete this activity
(including completion and submission of the learning assessment and
program evaluation) will be issued a statement of credit via
Note: The learning assessment is intended to help you evaluate your understanding of the material. A minimum passing score is not required.
Physicians.
The Meniscus Educational Institute (MEI) is
accredited by the Accreditation Council for Continuing Medical Education (ACCME)
to provide continuing education for physicians.
The Meniscus Educational Institute designates this educational activity for a maximum of 1 category 1 credit towards the AMA Physicians’ Recognition Award. Each physician should claim only those credits that he/she actually spent in the educational activity.
Nurses.
This activity for 1.2 contact hours is provided by the
Meniscus Educational Institute, which is accredited as a provider of continuing
nursing education by the American Nurses Credentialing Center’s Commission on
Accreditation.
Accreditation refers to recognition of educational activities only and does not imply approval or endorsement of any product by the American Nurses Credentialing Center’s Commission on Accreditation.
Provider approved by the California Board of Registered Nursing, Provider No.
13164, for
Meniscus Limited is committed to protecting the privacy of participants in our educational offerings. To read our full privacy policy, click here.